Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. - Wikidata - awgldk - TriplyDB

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

http://www.wikidata.org/entity/Q36011977

about

Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease.Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study.Cognitive reserve and brain reserve in prodromal Huntington's disease.A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data.Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease.Variability in interval production is due to timing-dependent deficits in Huntington's disease.Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study.A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease.Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues.Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden Interaction without intent: the shape of the social world in Huntington's disease Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease.The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory.Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease.Neuropsychiatry and White Matter Microstructure in Huntington's Disease Cognitive decline in prodromal Huntington Disease: implications for clinical trials.PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation.Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.Driving with a neurodegenerative disorder: an overview of the current literature.Behavioral testing of minipigs transgenic for the Huntington gene-A three-year observational study.The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study.Dual Task Performance May be a Better Measure of Cognitive Processing in Huntington's Disease than Traditional Attention Tests.Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.Diagnostic criteria for Huntington's disease based on natural history.HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures.The Neuropsychology of Huntington's Disease.Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.Revisiting the neuropsychiatry of Huntington's disease.Huntington's Disease: Premotor Phase.Evaluation of Cognition and Cortical Excitability in Huntington's Disease.Progress in developing transgenic monkey model for Huntington's disease.

P2860

Q27332203-17F32DED-CF92-4166-8899-42659BEFDA48 Q27333729-1E222958-0AFB-44D8-A86A-4E46BD1DCE24 Q27334759-FAB28A5A-F76F-4BDF-8F0B-F109F4E6E8EC Q30441887-13B82EF4-7F11-4890-A5C1-326A588B8537 Q30541757-51C8EC34-F025-4C49-8522-52C0BE6EC779 Q30622209-293AD6F0-BB8B-4F39-97B7-EDB18BA1C9C7 Q30670030-60CF6C7B-FCDF-48AB-9681-8C18CB01525F Q30862037-72A3A653-38C4-4E60-908B-7718EF7AFFBC Q33579030-4742F251-29B0-425A-A261-F237C826A60A Q34302108-F7400F98-9307-4708-BC03-94EDC1647767 Q34443430-5002C656-DFE0-4111-BB05-F98F4284FE88 Q35024584-7EF03258-2046-48B3-91A8-4B56F96EE117 Q35101600-F724E00C-9626-4A8B-9BD7-4D429F0D3225 Q35738853-2E355A64-D614-40E7-A8D0-4937324702C2 Q35997096-5C77F1ED-AB77-4E31-AB82-7E5EDB9DB2E6 Q36030634-7B76D342-CB0A-46FB-8E20-340C8CBAD470 Q36206024-724C653E-5D18-49B1-A245-13E471028ED2 Q36238024-9131D58D-38B6-448D-87E3-7C2EEBE01A69 Q36252810-71240989-6B6C-440C-A49A-39F31B2AE074 Q36384343-42CCB848-EE92-4C1F-B0D2-61CE5C13751B Q37227655-CFEABA7B-9333-40B2-B767-5D3B7470F9D7 Q37648786-A6DF984F-5D97-478D-9C4C-7DBD64BB1EA0 Q38202178-4280E136-BE71-4885-A71E-E2EB8F4C0145 Q38206500-776F72CC-2069-4906-93A6-A8E514C92E1C Q38248689-9ECE5DA2-0559-4622-AB58-F2D86FF1A385 Q39201203-D13907B6-E13F-46C3-938A-D9EB774E6A71 Q39251384-E50C1317-7FEA-48EA-8A11-6AA7EC5277D9 Q42708331-562F5BE8-74E2-424B-B987-A2D1264893F8 Q44295598-48E8A4ED-EB3D-47F2-ACC7-24D5B68B35F6 Q45290169-9B15A35C-0BDF-4C70-BB02-BD71D7DF3F26 Q45297368-00204FC3-21CF-41C6-8DE9-EDF4CE48E194 Q45301388-AC3FFA2F-BBFD-4A10-8AE3-AE55D071CDB9 Q45301633-A104E9B8-DCA5-4AFE-8DF5-086E256A0804 Q45302392-E5431654-D525-4EF0-957E-C84BBFEC5B3A Q45304583-D7223F2C-EECF-4DDD-AC92-D4D17CDBC708 Q45305483-54E19BBA-A639-497A-8B62-763E005D14E3 Q45305909-624A1DB8-4FDF-43EF-9E67-51B910DEC063 Q47288617-CF46ACF2-6ADA-4F11-A426-1917AACE8BEA Q47558279-B6AC3A15-82D3-4FB3-B241-982050A88187 Q47974512-17A30E42-37B9-4933-8BD2-A73B4E4701C9

P2860

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

http://www.wikidata.org/entity/Q36011977

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Evaluation of longitudinal 12 ...... nd early Huntington's disease.

@ast

Evaluation of longitudinal 12 ...... nd early Huntington's disease.

@en

type

label

Evaluation of longitudinal 12 ...... nd early Huntington's disease.

@ast

Evaluation of longitudinal 12 ...... nd early Huntington's disease.

@en

prefLabel

Evaluation of longitudinal 12 ...... nd early Huntington's disease.

@ast

Evaluation of longitudinal 12 ...... nd early Huntington's disease.

@en

P1433

Q36011977-9F69AA94-95B5-44B9-981C-28660D799014

P1476

Q36011977-62A7DA6E-2CB8-443E-AEB5-D0E672238F6A

P2093

Q36011977-0A671842-1A9D-4691-B3EE-7E932C98700E

Q36011977-2F6296D5-B8C2-4E8D-892A-A1EF98C4DDAF

Q36011977-335DF604-69CE-4D73-9D2E-3C5CCE95AC43

Q36011977-4276A338-7423-4ECC-B4A3-7600F949F066

Q36011977-57838FF5-E85F-44AF-BFCB-93B43CAE4DF7

Q36011977-6867023E-EA09-4364-9026-4E5947A9C25A

Q36011977-7A6B1DA6-33A6-483A-A946-D0953B278D29

Q36011977-87B54B26-93ED-4C41-838A-5386BDD88C21

Q36011977-93DDF469-BB10-4C35-8A8D-B083E5E6ABCF

Q36011977-A436BFEE-BA08-4ED4-8BD4-00C1EE300214

P2860

Q36011977-02B0BD78-5E91-464D-8D9C-57849E0BBCCE

Q36011977-431A5D77-EB42-4A34-AF13-CF459A5725F1

Q36011977-5561DFCF-240C-4286-8691-369E7CC70DA9

Q36011977-65AAD297-FBB9-4B33-B072-EFA46A6821B0

Q36011977-7380A17E-85F2-4888-9E45-B1B9519D9C22

Q36011977-961A8540-E6CA-42C4-B78F-9BE9AED6F033

Q36011977-AE315C3B-528E-4A26-A9B9-DC10488170E8

Q36011977-D015FBE8-F02F-41A3-A128-D42C73225165

Q36011977-E9D9F69D-753F-460E-AAA8-C4743A7D3CEA

Q36011977-EF681908-DCFA-4D02-A8DE-8DD35E5477CB

P304

Q36011977-C4AEEDDB-9AE2-4AAE-8240-6EC3AADC39BA

P31

Q36011977-AE3B2556-4101-49D4-8987-CC93B274D2CA

P356

Q36011977-8B9FCB76-3766-4AEE-835B-C7FF05A6E8BC

P407

Q36011977-07EB3F9D-638D-4472-BB65-9456CF23BECD

P433

Q36011977-BAE7D3BF-8A6F-491C-814A-2A665ABEF871

P478

Q36011977-1452E7C6-1CCB-4C0E-888E-5E3BBF5C74E7

P50

Q36011977-15A09503-6BEC-4B28-8B23-B342FF0C89FC

Q36011977-514230B5-FB26-4BE7-B466-C9A8B484052D

Q36011977-5B688F15-2C7D-4303-8A3F-8AEAB08469CF

Q36011977-B0F7F81C-9FFB-4358-A9FA-EC3C27CC5918

Q36011977-BF5C4EDA-DED2-426D-B624-5D922672EFC4

Q36011977-E160CAA3-F8DF-430E-A61F-8A7E806EBAB8

P577

Q36011977-033CB443-5DC8-4D8C-93F9-6A794FF102B7

P5875

Q36011977-63248D03-D6B8-4E5A-8321-A7538D7E7F81

P698

Q36011977-3CC9D547-68F6-41ED-A81D-8C2D5951D7A2

P921

Q36011977-74AC703F-CC21-431C-8A2E-763C3550F811

P932

Q36011977-9DDF3E5F-59EC-47DF-9781-94DE7301D85A

P356

JNNP-2011-301940

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Evaluation of longitudinal 12 ...... and early Huntington's disease

@en

P2093

Alexandra Dürr

http://www.w3.org/2001/XMLSchema#string

Alison M O'Regan

http://www.w3.org/2001/XMLSchema#string

Allison Coleman

http://www.w3.org/2001/XMLSchema#string

Damian Justo

http://www.w3.org/2001/XMLSchema#string

Ellen P Hart

http://www.w3.org/2001/XMLSchema#string

Eve M Dumas

http://www.w3.org/2001/XMLSchema#string

Miranda J Say

http://www.w3.org/2001/XMLSchema#string

Rachelle Dar Santos

http://www.w3.org/2001/XMLSchema#string

Raymund A Roos

http://www.w3.org/2001/XMLSchema#string

Rebecca Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Neurocognitive signs in prodromal Huntington disease.

Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

CAG repeat number governs the development rate of pathology in Huntington's disease.

High insulinlike growth factor I is associated with cognitive decline in Huntington disease.

Quantitative neuropathological changes in presymptomatic Huntington's disease.

Retest effects and cognitive decline in longitudinal follow-up of patients with early HD.

Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease.

P304

687-694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP-2011-301940

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Sarah J. Tabrizi

Izelle Labuschagne

Douglas R Langbehn

Blair R Leavitt

P577

2012-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224918990

http://www.w3.org/2001/XMLSchema#string

P698

22566599

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3368487

http://www.w3.org/2001/XMLSchema#string